Inhaled IL-2 Stabilizes Pulmonary Metastases of Renal Cell Cancer
September 1st 1997SAN FRANCISCO-The search for less invasive and less toxic methods to deliver interleukin-2 (IL-2) has moved beyond injection. Edith Huland, MD, PhD, of the University Clinic Eppendorf, Hamburg, Germany, has been using a nebulizer to deliver IL-2 for six years.
Outpatient Biochemotherapy Safe, Effective in Renal Cell Cancer
September 1st 1997SAN FRANCISCO-An outpatient combination of low-dose interleukin-2 (IL-2, Proleukin), interferon alfa-2b (Intron A), and fluorouracil appears to offer response and survival rates similar to high-dose IL-2 with minimal side effects, according to studies conducted by Jens Atzpodien, MD, associate professor of medicine, Medizinische Hochschule, Hannover, Germany.
Obstacles to Advance Directives May Include Physicians
September 1st 1997NEW YORK-The majority of people in the United States die without discussing or documenting their wishes regarding end-of-life care. Estimates of the number of people who have actually prepared advance directives range from 5% to 25%, said Sylvia Pearl, LCSW, during a national teleconference sponsored by Cancer Care, Inc.
Neuropsychiatric Syndromes Prevalent Among CNS Cancer Patients
September 1st 1997HOUSTON-Approximately 50% to 80% of patients with central nervous system tumors experience emotional and behavioral changes that significantly alter their capacity to function independently and interact in a healthy manner, Alan D. Valentine, MD, said at a symposium on cancer and the central nervous system. In fact, he added, behavioral changes may be one of the first signs that a patient is seriously ill.
Once-Daily Sustained-Release Morphine Effective for Cancer Pain
September 1st 1997ADELAIDE, Australia-A sustained-release morphine formulation that can be administered once or twice a day (Kadian) showed similar efficacy and safety to a standard twice-daily morphine formulation (MS Contin) in a multicen-ter, placebo-controlled US study of cancer pain patients, sponsored by the Australian manufacturers of Kadian.
Long-Term Dronabinol Use Safe, Effective for AIDS Anorexia
September 1st 1997COLUMBUS, Ohio-A new multi-center study supports the long-term use of dronabinol (Marinol) for anorexia associated with weight loss in patients with AIDS. Dronabinol is a synthetically produced delta-9-tetrahydrocannabinol, the active constituent of marijuana.
Cancer Patients Use Music to Soothe Presurgical Anxiety
September 1st 1997NEW ORLEANS-Surgical oncol-ogy patients appear to be overwhelmingly in favor of listening to music before and after their surgery. Besides its soothing powers, music may help in pain control, offering a cost-effective intervention, investigators reported at the Oncology Nursing Society.
FDA Approves Taxol for Use in AIDS-Related KS
September 1st 1997ROCKVILLE, Md-The Food and Drug Administration (FDA) has cleared Bristol-Myers Squibb’s Taxol (paclitaxel) Injection for use in the second-line treatment of AIDS-related Kaposi’s sarcoma (KS). Taxol is also approved for second-line use in metastatic breast and ovarian cancer.
AACR Urges Tobacco Industry Support of Cancer Research
September 1st 1997PHILADELPHIA-The proposed tobacco settlement should include support for federally funded cancer research “in proportion to the devastation caused by tobacco-induced cancers on our public health,” the American Association for Cancer Research said in a position statement.
Panel Gives Platelet Growth Factor Nod of Approval
September 1st 1997MADISON, NJ-The Biological Response Modifiers Advisory Committee unanimously recommended that the Food and Drug Administration approve Neumega (recombinant human inter-leukin-11 or rhIL-11), Genetics Institute’s platelet growth factor. Genetics Institute is a subsidiary of American Home Products Corporation.
Panel Recommends FDA Approve First MoAb for Cancer Rx
September 1st 1997BETHESDA, Md-The Biological Response Modifiers Advisory Committee has recommended that the FDA usher cancer therapy into a new era by approving IDEC Pharamceutical’s Rituxan (rituximab) for patients with relapsed or refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma.
Clinton Proposes New Law on Patient Privacy
September 1st 1997WASHINGTON-The Clinton Administration soon will propose a federal law aimed at protecting the privacy of medical records. The law would allow disclosure of medical records only for reasons of health care. For example, if an employer gained access to an employee’s records during the claims process, the company would not be allowed to use the information in any way that would affect the employee’s job, such as in considering promotions or assignments.
Society of Surgical Oncology Practice Guidelines: Introductory Remarks
September 1st 1997Thousands of practice guidelines/practice parameters have been published by various professional organizations. The American Medical Association,[1] American College of Physicians,[2,3] and others[4-6] have written extensively about
Prostate-Specific Antigen: What’s New in 1997
September 1st 1997This review of prostate-specific antigen (PSA) by Pannek and Partin, two experts in the prostate marker field, comes at a very good time-a point at which great changes are occurring after a relatively long period of stability. I expect that this trend will continue. Moreover, given the rapid developments occurring in this area, some of the statements made in both the review and my commentary will probably need to be modified within the next 12 months, with further revisions necessary thereafter.
Precise Clinical Staging Allows Treatment Modification of Patients With Esophageal Carcinoma
September 1st 1997Treatment of esophageal carcinoma requires the realization that this neoplasm is not a single entity with a uniformly poor prognosis. As with any other malignancy, disease stage has prognostic and therapeutic
Two-Step Approach Urged to Avoid High Tech, Wild Death
August 1st 1997HOUSTON--In the current health care environment, peaceful deaths are seriously threatened as clinicians attempt technological brinkmanship and patients and families demand that "everything be done" to extend life, said Rebecca Pentz, PhD, a clinical ethicist at The University of Texas M.D. Anderson Cancer Center.
Health Insurance Premiums Tax Proposed
August 1st 1997WASHINGTON--To maintain its world leadership in clinical care, the nation should levy a 1% tax on health care premiums to pay for clinical research, Kenneth I. Shine, MD, president of the National Academy of Sciences' Institute of Medicine (IOM), has proposed.
ODAC Votes Yes on Taxol for Kaposi's Sarcoma
August 1st 1997BETHESDA, Md--The FDA's Oncology Drugs Advisory Committee (ODAC) voted 8 to 4 to recommend that the agency grant traditional new drug approval to Bristol-Myers Squibb's Taxol for Injection Concentrate (paclitaxel) for the second-line treatment of AIDS-related Kaposi's sarcoma (KS).
Five Principles Help Resolve Ethical Dilemmas in Care
August 1st 1997SEATTLE--Physicians and nurses frequently confront ethical dilemmas in caring for cancer patients, and these must be resolved on an individual basis, through established principles, Tom McCormick, DMin, senior lecturer in medical ethics, University of Washington, told the Association of Pediatric Oncology Nurses. "I don't think we'll ever see the day," he said, "when we can put all of the alternatives into a computer, press a button, and ask the computer to come up with a decision."